Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F17%3A00481118" target="_blank" >RIV/86652036:_____/17:00481118 - isvavai.cz</a>
Result on the web
<a href="http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2014256546" target="_blank" >http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2014256546</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
Original language description
The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivativesnof tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixturen(MitoTAX). Alkyl triphenylphosphonium derivatives oftamoxifen have the general formula (I), where n=8 to 12 and where Z is selectednfrom the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the generalnformula IA, where n = 6 to l 0 and where Z has the above mentioned meaning. These compounds are applicable for the treatment ofnneoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to theninvention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I)nand/or IA or their corresponding salts of tertiary amine.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
AU2014256546
Publisher
AU001 -
Publisher name
IP Australia
Place of publication
Phillip ACT
Publication country
AU - AUSTRALIA
Date of acceptance
Jul 13, 2017
Owner name
J. Neužil, Biotechnologický ústav AV ČR, v. v. i., Smart Brain s.r.o., KKCG AG
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)